SCHEMBL1756239

SCHEMBL1756239

COC(=O)C(NC(=O)c1ncc(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)s1)C(C)C

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 9/20 0.83
CSGALNACT1 Q8TDX6 1/20 0.56
KDR P35968 6/20 0.53
PDGFRB P09619 1/20 0.53
MAPT P10636 3/20 0.52
NPC1 O15118 1/20 0.52
CDK8 P49336 1/20 0.48
CDK7 P50613 1/20 0.48
CDK6 Q00534 1/20 0.48
MAPK14 Q16539 1/20 0.47
TNNI3K Q59H18 1/20 0.47
MEN1 O00255 2/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TEK Q02763 2/20 0.47
KIT P10721 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756276 0.91 DGAT1 (1.00) DGAT1CSGALNACT1KDRPDGFRBMAPT
SCHEMBL1756268 0.87 DGAT1 (0.64) DGAT1CSGALNACT1KDRPDGFRB
SCHEMBL1756271 0.87 DGAT1 (0.64) DGAT1CSGALNACT1KDRPDGFRB
SCHEMBL1756331 0.86 DGAT1 (0.62) DGAT1CSGALNACT1KDRCDK8TEK
SCHEMBL1756333 0.86 DGAT1 (0.62) DGAT1CSGALNACT1KDRCDK8TEK
SCHEMBL1756215 0.83 DGAT1 (0.59) DGAT1CSGALNACT1KDRPDGFRBMAPT
SCHEMBL1756233 0.83 DGAT1 (0.64) DGAT1MEN1KMT2ASMN1; SMN2
SCHEMBL1756236 0.83 DGAT1 (0.64) DGAT1MEN1KMT2ASMN1; SMN2
SCHEMBL2293738 0.82 MAPK1 (0.58) DGAT1CSGALNACT1KDRPDGFRBMAPT
SCHEMBL2293740 0.82 MAPK1 (0.58) DGAT1CSGALNACT1KDRPDGFRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US claimed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP claimed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US claimed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO claimed
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US disclosed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US disclosed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY DGAT1, DGAT2, DLAT DGAT1 1/4885CSGALNACT1 555/4885KDR 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.